What changed
$CAH — Distributes pharmaceuticals and medical supplies globally.
🎯 Q1 FY26 | Rev $61B | EPS $3.17 vs $2.79 🟢 | Margin 1.6%
💡 Consensus expects CAH to be a low-growth, low-margin distributor with FY26 EPS of ~$10.77. The 13.7% EPS beat (actual $3.17 vs est $2.79) and raised guidance suggest operating leverage is improving faster than modeled, driven by pharma segment scale and cost controls.
🏢 Business Quality: 7/10 | Valuation: fair
📉 Reward/Risk: Upside 12% to $248 (20x FY27 EPS of $12.40) vs downside 8% to $204 (18x FY26 consensus of $11.33). Ratio 1.5:1.
🔮 Catalyst: Q4 FY26 earnings (expected Aug 2026): confirm raised guidance and show continued margin expansion. Metric to watch: Non-GAAP operating margin >1.7%. Failure signal: guidance cut or margin contraction.
💰 Entry: Current price $221.38 is attractive for a 3-month horizon.
Also in play: $A $G $WU $PYPL $SQ $FIS